Vyoral Daniel
Institute of Hematology and Blood Transfusion, Prague, Czechia; Institute of Pathological Physiology, First Faculty of Medicine,Charles University, Prague, Czechia.
BIOCEV, First Faculty of Medicine, Charles University, Prague, Czechia; Institute of Hematology and Blood Transfusion, Prague, Czechia.
Pharmacol Res. 2017 Jan;115:242-254. doi: 10.1016/j.phrs.2016.11.010. Epub 2016 Nov 17.
Iron is an essential biogenic element for both prokaryotic and eukaryotic cells. In humans iron is present in hundreds of different metalloproteins. The peptide hormone hepcidin serves as a master regulator of iron homeostasis on the level of single cells and whole organism - by altering cell surface expression of cellular iron exporter - protein ferroportin. Altered levels of extracellular hepcidin lead to pathological conditions such as hemochromatosis and iron loading or, on the other side, iron restrictive anemias. Therapeutic modulation of hepcidin is a new and promising approach to treatment of these conditions. In this review, a summary of the current knowledge of hepcidin function, regulation and pathological involvements are provided, followed by a section covering the therapeutic potential of hepcidin and the current strategies how to modulate its levels and biological functions for therapeutic purposes.
铁是原核细胞和真核细胞必需的生物元素。在人体中,铁存在于数百种不同的金属蛋白中。肽激素铁调素通过改变细胞铁输出蛋白铁转运蛋白的细胞表面表达,在单细胞和整个生物体水平上作为铁稳态的主要调节因子。细胞外铁调素水平的改变会导致病理状况,如血色素沉着症和铁过载,或者另一方面导致缺铁性贫血。铁调素的治疗性调节是治疗这些病症的一种新的且有前景的方法。在本综述中,提供了关于铁调素功能、调节和病理参与的当前知识的总结,随后是一部分内容,涵盖铁调素的治疗潜力以及当前为治疗目的调节其水平和生物学功能的策略。